Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer....pdf (1.72 MB)
Download file

Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: comparative analysis with standard clinicopathological factors

Download (1.72 MB)
journal contribution
posted on 23.06.2022, 08:23 by Seodhna M Lynch, Niamh M Russell, Stephen Barron, Chan-Ju A Wang, Tony Loughman, Peter Dynoodt, Bozena Fender, Cesar Lopez-Ruiz, Anthony O'GradyAnthony O'Grady, Katherine SheehanKatherine Sheehan, Joanna FayJoanna Fay, Verena Amberger-Murphy, Anurati Saha, Rut Klinger, Claudia A Gonzalez, Nebras Al-Attar, Arman Rahman, Desmond O'Leary, Fiona T Lanigan, Adrian P Bracken, John Crown, Catherine M Kelly, Darran O'ConnorDarran O'Connor, William M Gallagher

Aim: The aim of the study was to assess the prognostic performance of a 6-gene molecular score (OncoMasTR Molecular Score [OMm]) and a composite risk score (OncoMasTR Risk Score [OM]) and to conduct a within-patient comparison against four routinely used molecular and clinicopathological risk assessment tools: Oncotype DX Recurrence Score, Ki67, Nottingham Prognostic Index and Clinical Risk Category, based on the modified Adjuvant! Online definition and three risk factors: patient age, tumour size and grade.

Methods: Biospecimens and clinicopathological information for 404 Irish women also previously enrolled in the Trial Assigning Individualized Options for Treatment [Rx] were provided by 11 participating hospitals, as the primary objective of an independent translational study. Gene expression measured via RT-qPCR was used to calculate OMm and OM. The prognostic value for distant recurrence-free survival (DRFS) and invasive disease-free survival (IDFS) was assessed using Cox proportional hazards models and Kaplan-Meier analysis. All statistical tests were two-sided ones.

Results: OMm and OM (both with likelihood ratio statistic [LRS] P < 0.001; C indexes = 0.84 and 0.85, respectively) were more prognostic for DRFS and provided significant additional prognostic information to all other assessment tools/factors assessed (all LRS P ≤ 0.002). In addition, the OM correctly classified more patients with distant recurrences (DRs) into the high-risk category than other risk classification tools. Similar results were observed for IDFS.

Discussion: Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification tool for identifying DR. A concise 6-gene signature with superior risk stratification was shown to increase prognosis reliability, which may help clinicians optimise treatment decisions.

Trial registration: ClinicalTrials.gov NCT02050750 NCT00310180.

Funding

European Union’s Horizon 2020 research and innovation programme awarded to OncoMark under grant agreement number 698630

Irish Cancer Society Collaborative Cancer Research Centre BREAST-PREDICT (grant number: CCRC13GAL)

Science Foundation Ireland (SFI) under the Investigator Programme OPTi-PREDICT (grant number: 15/IA/3104)

Strategic Research Programme Precision Oncology Ireland (grant number: 18/SPP/ 3522)

SFI (grant number: 12TIDAB2436 and 18/SPP/3522)

SFI Career Development Award (grant number: 15/ CDA/3438)

History

Comments

The original article is available at https://www.ejcancer.com/

Published Citation

Lynch SM. et al. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: comparative analysis with standard clinicopathological factors. Eur J Cancer. 2021 Jul;152:78-89

Publication Date

2 June 2021

PubMed ID

34090143

Department/Unit

  • Beaumont Hospital
  • Pathology
  • School of Pharmacy and Biomolecular Sciences

Research Area

  • Cancer

Publisher

Elsevier BV

Version

  • Published Version (Version of Record)